AR093519A1 - 1,6-naftiridinas sustituidas - Google Patents

1,6-naftiridinas sustituidas

Info

Publication number
AR093519A1
AR093519A1 ARP130104234A ARP130104234A AR093519A1 AR 093519 A1 AR093519 A1 AR 093519A1 AR P130104234 A ARP130104234 A AR P130104234A AR P130104234 A ARP130104234 A AR P130104234A AR 093519 A1 AR093519 A1 AR 093519A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
optionally substituted
substituted
halogen
alkoxy
Prior art date
Application number
ARP130104234A
Other languages
English (en)
Spanish (es)
Inventor
M Ceccarelli Simona
Jagasia Ravi
E Martin Rainer
Peters Jens
Uwe - Wichmann Juergen
Jakob-Roetne Roland
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR093519A1 publication Critical patent/AR093519A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
ARP130104234A 2012-11-20 2013-11-18 1,6-naftiridinas sustituidas AR093519A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12193311 2012-11-20

Publications (1)

Publication Number Publication Date
AR093519A1 true AR093519A1 (es) 2015-06-10

Family

ID=47189816

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104234A AR093519A1 (es) 2012-11-20 2013-11-18 1,6-naftiridinas sustituidas

Country Status (13)

Country Link
US (1) US9657014B2 (2)
EP (1) EP2922540A1 (2)
JP (1) JP2016505534A (2)
KR (1) KR20150085538A (2)
CN (1) CN104812387A (2)
AR (1) AR093519A1 (2)
BR (1) BR112015011094A2 (2)
CA (1) CA2890685A1 (2)
HK (1) HK1207317A1 (2)
MX (1) MX2015006364A (2)
RU (1) RU2015120217A (2)
TW (1) TW201425312A (2)
WO (1) WO2014079787A1 (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI529171B (zh) 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 1,7-萘啶衍生物
JP2017522324A (ja) * 2014-07-17 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 新規ナフチリジン及びイソキノリンならびにcdk8/19阻害剤としてのその使用
EP3256217A1 (en) * 2015-02-11 2017-12-20 Basilea Pharmaceutica International AG Substituted mono- and polyazanaphthalene derivatives and their use
AU2016236669B2 (en) 2015-03-24 2018-11-08 Shanghai Yingli Pharmaceutical Co., Ltd Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
BR112018008630A2 (pt) * 2015-11-06 2018-10-30 Neurocrine Biosciences Inc derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida, seus usos, composição farmacêutica
EA039638B1 (ru) * 2016-01-06 2022-02-21 Нейрокрин Байосайенсиз, Инк. Антагонисты мускаринового рецептора 4 и способы их применения
EP3591040A4 (en) 2017-03-03 2020-11-11 Kyoto University METHOD OF PRODUCTION OF PANCREATIC PROGENITOR CELLS
BR112021012950A2 (pt) 2019-01-03 2021-09-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Métodos e materiais para aumentar os níveis de polipeptídeo do fator de transcrição eb
US12486250B2 (en) 2019-12-06 2025-12-02 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
JP2024508761A (ja) * 2020-12-18 2024-02-28 ザ スクリプス リサーチ インスティテュート 神経変性、変性及び代謝性障害の処置のための化合物並びにその使用
WO2025252732A1 (en) * 2024-06-04 2025-12-11 Syngenta Crop Protection Ag Nitrogen-containing 6-membered bicyclic derivatives with microbiocidal activity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605437D0 (en) 1996-03-15 1996-05-15 Iaf Biochem Int Cytomegalovirus inhibiting compounds
CN1283995A (zh) * 1997-12-11 2001-02-14 生化制药有限公司 抗病毒化合物
AU2002218902A1 (en) 2000-12-27 2002-07-08 Shire Biochem Inc. Macrocyclic anti-viral compounds
US7282506B2 (en) * 2004-08-03 2007-10-16 Serenex, Inc. 2,8-disubstituted naphthyridine derivatives
FR2904317A1 (fr) 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
US20080242694A1 (en) 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
WO2008046072A2 (en) 2006-10-13 2008-04-17 The Board Of Regents Of The University Of Texas System Chemical inducers of neurogenesis
CN102325754B (zh) * 2009-01-19 2014-03-12 第一三共株式会社 含杂原子的环状化合物
AU2010221417A1 (en) * 2009-03-02 2011-09-22 Sirtris Pharmaceuticals, Inc. 8-substituted quinolines and related analogs as sirtuin modulators
KR20120006016A (ko) * 2009-04-06 2012-01-17 다이이찌 산쿄 가부시키가이샤 치환 페닐기를 갖는 고리형 화합물
CA2804161A1 (en) 2010-07-07 2012-01-12 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
JP2012036168A (ja) 2010-07-15 2012-02-23 Daiichi Sankyo Co Ltd ヘテロ原子を有する環状化合物を含有する医薬組成物

Also Published As

Publication number Publication date
CA2890685A1 (en) 2014-05-30
US9657014B2 (en) 2017-05-23
JP2016505534A (ja) 2016-02-25
US20150252044A1 (en) 2015-09-10
RU2015120217A (ru) 2017-01-10
KR20150085538A (ko) 2015-07-23
MX2015006364A (es) 2015-10-05
TW201425312A (zh) 2014-07-01
CN104812387A (zh) 2015-07-29
WO2014079787A1 (en) 2014-05-30
EP2922540A1 (en) 2015-09-30
BR112015011094A2 (pt) 2017-07-11
HK1207317A1 (en) 2016-01-29

Similar Documents

Publication Publication Date Title
AR093519A1 (es) 1,6-naftiridinas sustituidas
AR097088A1 (es) Derivados de 1,7-naftiridina
AR096371A1 (es) 2-fenilimidazo[1,2-a]pirimidinas
AR096640A1 (es) Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona
MX2016008842A (es) Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos.
AR093576A1 (es) Derivados heterociclicos sustituidos
AR106588A1 (es) Derivados de indolin-2-ona para el tratamiento de enfermedades del snc
MY186124A (en) Indolin-2-one or pyrrolo-pyridin-2-one derivatives
AR080083A1 (es) Moduladores de gamma-secretasa
MX2015015052A (es) Derivados de isoquinolina que estimulan la neurogenesis.
MX381925B (es) Peliculas termocontraibles de barrera de multicapa pvdc.
AR060647A1 (es) Derivados de piperidina con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico, composiciones farmaceuticas que los comprenden, el uso de los mismos para la fabricacion de medicamentos para el tratamiento de afecciones pulmonares, metodos para preparar estos der
AR106590A1 (es) Derivados de indolin-2-ona
AR073794A1 (es) Derivados heterociclicos de triazinas sustituidas, medicamentos que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento del alzheimer y otro tipo de demencias.
AR077960A1 (es) Derivados de benzamida n-sustituidos como inhibidores del transportador de glicina 1 (glyt-1)
CO6341621A2 (es) Piperidinas arilamino y heteroarilamino sustituidas como inhibidores de glyt-1
PH12016500605A1 (en) Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders
AR092041A1 (es) Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona
AR100532A1 (es) Derivados de indolín-2-ona y 1,3-dihidro-pirrolo[3,2-c]piridín-2-ona
MX363461B (es) Derivados de benzisoxazol como moduladores de la neurogénesis y el uso de los mismos en el tratamiento de enfermedades neurológicas y trastornos neuropsiquiátricos.
AR095970A1 (es) Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona como estimuladores de nsc
AR075032A1 (es) Pirazinonas sustituidas
MX2016001528A (es) Derivados de indol-carboxamida.
TH165816A (th) ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท

Legal Events

Date Code Title Description
FB Suspension of granting procedure